WO2013127782A3 - Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur - Google Patents

Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur Download PDF

Info

Publication number
WO2013127782A3
WO2013127782A3 PCT/EP2013/053800 EP2013053800W WO2013127782A3 WO 2013127782 A3 WO2013127782 A3 WO 2013127782A3 EP 2013053800 W EP2013053800 W EP 2013053800W WO 2013127782 A3 WO2013127782 A3 WO 2013127782A3
Authority
WO
WIPO (PCT)
Prior art keywords
genes
heart
storage diseases
individual forms
markers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2013/053800
Other languages
German (de)
English (en)
Other versions
WO2013127782A2 (fr
Inventor
Uwe Kühl
Heinz-Peter Schultheiss
Dirk Lassner
Maria ROHDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IKDT INSTITUT KARDIALE DIAGNOSTIK und THERAPIE GmbH
Charite Universitaetsmedizin Berlin
Original Assignee
IKDT INSTITUT KARDIALE DIAGNOSTIK und THERAPIE GmbH
Charite Universitaetsmedizin Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IKDT INSTITUT KARDIALE DIAGNOSTIK und THERAPIE GmbH, Charite Universitaetsmedizin Berlin filed Critical IKDT INSTITUT KARDIALE DIAGNOSTIK und THERAPIE GmbH
Priority to DE112013001154.9T priority Critical patent/DE112013001154A5/de
Priority to EP13712154.7A priority patent/EP2820131A2/fr
Publication of WO2013127782A2 publication Critical patent/WO2013127782A2/fr
Publication of WO2013127782A3 publication Critical patent/WO2013127782A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation de certains micro-ARN et/ou gènes, individuellement ou en association sous forme de profils comme marqueurs pour l'identification de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur, ainsi que leur utilisation dans des systèmes de diagnostic pour l'identification de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur, ces systèmes présentant au moins une partie de ces micro-ARN et/ou gènes. L'invention concerne en outre un procédé d'identification et de différenciation de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur au moyen d'au moins certains de ces micro-ARN et/ou gènes. L'invention concerne par ailleurs un médicament qui contient au moins un acide nucléique présentant une séquence identique à la séquence d'un de ces micro-ARN ou complémentaire de celle-ci.
PCT/EP2013/053800 2012-02-27 2013-02-26 Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur Ceased WO2013127782A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
DE112013001154.9T DE112013001154A5 (de) 2012-02-27 2013-02-26 Verwendung von microRNAs oder Genen als Marker zur Identifizierung, Diagnose und Therapie einzelner Formen nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
EP13712154.7A EP2820131A2 (fr) 2012-02-27 2013-02-26 Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du c ur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101557A DE102012101557A1 (de) 2012-02-27 2012-02-27 Verwendung von microRNAs oder Genen als Marker zur Identifizierung, Diagnose und Therapie einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
DE102012101557.0 2012-02-27

Publications (2)

Publication Number Publication Date
WO2013127782A2 WO2013127782A2 (fr) 2013-09-06
WO2013127782A3 true WO2013127782A3 (fr) 2013-11-21

Family

ID=47997358

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/053800 Ceased WO2013127782A2 (fr) 2012-02-27 2013-02-26 Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur

Country Status (3)

Country Link
EP (1) EP2820131A2 (fr)
DE (2) DE102012101557A1 (fr)
WO (1) WO2013127782A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104450698A (zh) * 2014-12-11 2015-03-25 中国计量学院 一种蜘蛛线粒体nd4基因全序列扩增引物及鉴定方法
WO2016133395A1 (fr) 2015-02-20 2016-08-25 Rijksuniversiteit Groningen Miarn circulants chez des patients atteints d'une insuffisance cardiaque aiguë
EP4417706A3 (fr) * 2015-05-08 2025-02-12 Agency For Science, Technology And Research Procédé de diagnostic et de pronostic d'insuffisance cardiaque chronique
DE102015216521B3 (de) * 2015-08-28 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Verwendung spezifischer Gene zur diagnostischen Abgrenzung einer eosinophilen Myokarditis von anderen fulminanten entzündlichen Herzmuskelerkrankungen
DE102015216782B3 (de) * 2015-09-02 2017-01-26 Ikdt Institut Kardiale Diagnostik Und Therapie Gmbh Verwendung von im Blutserum oder Blutplasma zirkulierenden microRNAs zur Identifikation biopsiepflichtiger Patienten und als Marker zur Differentialdiagnose einzelner nicht-ischämischer Kardiomyopathien oder Speichererkrankungen des Herzens
WO2017076974A1 (fr) * 2015-11-05 2017-05-11 Academisch Medisch Centrum Biomarqueur pour la stratification du risque dans une maladie cardiovasculaire
EP3375458A1 (fr) * 2017-03-14 2018-09-19 I.C.G.E.B. International Centre for Genetic Engineering and Biotechnology Micro-arn hsa-mir-665 dans l'hypertrophie cardiaque
US11225660B2 (en) 2017-10-12 2022-01-18 Emory University Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
CN108611421B (zh) * 2018-05-15 2021-07-27 唐山市人民医院 检测食管鳞癌标记物microRNA-10b-3p及在试剂盒中的应用
CN112638475B (zh) * 2018-06-28 2024-12-06 英国研究与创新基金会 用于治疗心脏病的microRNA靶向剂
JP2022510488A (ja) * 2018-12-10 2022-01-26 セラ プログノスティックス， インコーポレイテッド 胎盤機能不全のための核酸バイオマーカー
EP3674420A1 (fr) * 2018-12-28 2020-07-01 Fundación Para la Investigación del Hospital Universitario y Politécnico La Fe de la Comunidad Valenciana Procédé pour prédire le risque de cardiotoxicité chez des patients atteints de cancer recevant une chimiothérapie aux anthracyclines
CN111154870B (zh) * 2019-08-05 2023-06-23 江苏省肿瘤医院 一种鼻咽癌转移诊断和/或预后评估的生物标记
EP4206334A4 (fr) * 2020-08-28 2025-01-01 Industry Academic Cooperation Foundation Keimyung University Biomarqueur micro-arn pour prédire une réponse médicamenteuse à des antidiabétiques et utilisation associée
CN112961912A (zh) * 2020-12-31 2021-06-15 郑州大学第一附属医院 外泌体miRNA作为诊断冠心病的分子标志物及其应用
CN112813158B (zh) * 2021-03-11 2022-12-13 石家庄市人民医院 心肌纤维化疾病辅助诊断相关的miRNA标志物及其应用
CN113846098B (zh) * 2021-09-18 2024-06-25 中国医学科学院基础医学研究所 一种小rna及其在心血管疾病治疗中的用途
CN114081895B (zh) * 2021-11-18 2023-08-04 佳木斯大学 一种用于治疗糖尿病性视网膜病变的miRNA及其应用
CN115418397B (zh) * 2022-04-19 2023-09-19 刘琳 一种用于扩张型心肌病辅助诊断的生物标志物及其应用
CN119082291A (zh) * 2024-09-24 2024-12-06 中国人民解放军总医院第二医学中心 用于诊断评估心肌衰老的miRNA标志物、试剂盒及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (fr) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2009151600A2 (fr) * 2008-06-10 2009-12-17 Tufts University Les protéines smad contrôlent la maturation des arnmi médiée par drosha
WO2010141546A1 (fr) * 2009-06-02 2010-12-09 University Of Miami Biomarqueurs transcriptomiques de diagnostic dans des cardiomyopathies inflammatoires
WO2011072177A2 (fr) * 2009-12-09 2011-06-16 Aviir, Inc. Dosage de biomarqueurs pour le diagnostic et le classement des maladies cardiovasculaires

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2693031A1 (fr) * 2007-07-18 2009-01-22 The Regents Of The University Colorado Expression differentielle de microarn de curs humains non insuffisants contre des coeurs humains insuffisants
WO2009033185A1 (fr) * 2007-09-06 2009-03-12 University Of Massachusetts SIGNATURES D'ARNmi SPÉCIFIQUE À UN VIRUS DESTINÉES AU DIAGNOSTIC ET AUX TRAITEMENT D'INFECTIONS VIRALES
IE20090047A1 (en) * 2009-02-26 2010-09-29 Nat Univ Ireland Protein targets in disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008042231A2 (fr) * 2006-09-29 2008-04-10 Children's Medical Center Corporation Compositions et méthodes d'évaluation et de traitement de l'insuffisance cardiaque
WO2009151600A2 (fr) * 2008-06-10 2009-12-17 Tufts University Les protéines smad contrôlent la maturation des arnmi médiée par drosha
WO2010141546A1 (fr) * 2009-06-02 2010-12-09 University Of Miami Biomarqueurs transcriptomiques de diagnostic dans des cardiomyopathies inflammatoires
WO2011072177A2 (fr) * 2009-12-09 2011-06-16 Aviir, Inc. Dosage de biomarqueurs pour le diagnostic et le classement des maladies cardiovasculaires

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
B. HEIDECKER ET AL: "Transcriptomic Biomarkers for the Accurate Diagnosis of Myocarditis", CIRCULATION, vol. 123, no. 11, 7 March 2011 (2011-03-07), pages 1174 - 1184, XP055062635, ISSN: 0009-7322, DOI: 10.1161/CIRCULATIONAHA.110.002857 *
BENAKANAKERE MANJUNATHA R ET AL: "Modulation of TLR2 Protein Expression by miR-105 in Human Oral Keratinocytes", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 284, no. 34, 21 August 2009 (2009-08-21), pages 23107 - 23115, XP002544552, ISSN: 0021-9258, [retrieved on 20090609], DOI: 10.1074/JBC.M109.013862 *
FICHTLSCHERER STEPHAN ET AL: "Circulating microRNAs: biomarkers or mediators of cardiovascular diseases?", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, HIGHWIRE PRESS, PHILADELPHIA, PA, US, vol. 31, no. 11, November 2011 (2011-11-01), pages 2383 - 2390, XP008147068, ISSN: 1524-4636, DOI: 10.1161/ATVBAHA.111.226696 *
GERMAN HEART FAILURE NETWORK ET AL: "Gene expression profiling from endomyocardial biopsy tissue allows distinction between subentities of dilated cardiomyopathy", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 136, no. 2, 12 May 2008 (2008-05-12), pages 360 - 369.e1, XP023610234, ISSN: 0022-5223, [retrieved on 20080512], DOI: 10.1016/J.JTCVS.2008.03.016 *
HIDEHITO FUNAHASHI ET AL: "Altered microRNA expression associated with reduced catecholamine sensitivity in patients with chronic heart failure", JOURNAL OF CARDIOLOGY, vol. 57, no. 3, 2 March 2011 (2011-03-02), pages 338 - 344, XP055062634, ISSN: 0914-5087, DOI: 10.1016/j.jjcc.2011.01.009 *
KASEY C. VICKERS ET AL: "MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins", NATURE CELL BIOLOGY, vol. 13, no. 4, 20 March 2011 (2011-03-20), pages 423 - 433, XP055062682, ISSN: 1465-7392, DOI: 10.1038/ncb2210 *
M. F. CORSTEN ET AL: "Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease", CIRCULATION: CARDIOVASCULAR GENETICS, vol. 3, no. 6, 4 October 2010 (2010-10-04), pages 499 - 506, XP055062726, ISSN: 1942-325X, DOI: 10.1161/CIRCGENETICS.110.957415 *
S. V. NAGA PRASAD ET AL: "Unique MicroRNA Profile in End-stage Heart Failure Indicates Alterations in Specific Cardiovascular Signaling Networks", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 284, no. 40, 29 July 2009 (2009-07-29), pages 27487 - 27499, XP055062050, ISSN: 0021-9258, DOI: 10.1074/jbc.M109.036541 *
See also references of EP2820131A2 *

Also Published As

Publication number Publication date
WO2013127782A2 (fr) 2013-09-06
DE112013001154A5 (de) 2014-12-11
DE102012101557A1 (de) 2013-08-29
EP2820131A2 (fr) 2015-01-07

Similar Documents

Publication Publication Date Title
WO2013127782A3 (fr) Utilisation de micro-arn ou de gènes comme marqueurs pour l'identification, le diagnostic et le traitement de formes individuelles de cardiomyopathies non ischémiques ou de maladies de surcharge du cœur
IL285107A (en) Diagnostic, prognostic and therapeutic uses of long non-coding RNA molecules for heart diseases and rehabilitation medicine
WO2012174256A3 (fr) Profils de méthylation de l'adn dans le cancer
EP4397760C0 (fr) Composition pour le clivage d'un adn cible comprenant un arn guide spécifique de l'adn cible et un acide nucléique codant pour la protéine cas ou la protéine cas, et leur utilisation
MX356625B (es) Oligonucleotidos para elaborar un cambio en la secuencia de una molécula de ácido ribonucleico objetivo presente en una célula viva.
WO2009111375A3 (fr) Traitement, diagnostic et procédé pour découvrir un antagoniste à l'aide d'arnmi spécifique de sparc
IL229070A0 (en) Methods for identifying and diagnosing lung diseases using their classification systems and sets
GB2500120B (en) Method of producing fluid identification system including DNA
IL250539A0 (en) Nucleotides modified for nucleic acid synthesis, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
HK1203513A1 (en) Methods of preparing substituted nucleotide analogs
WO2013170170A3 (fr) Compositions et méthodes de thérapie génique
AU2012205878A8 (en) miRNA for treating diseases and conditions associated with neo-angiogenesis
EP4501318A3 (fr) Vaccins d'acides nucléiques
BR112014018916A2 (pt) classe de genes de resistência a glifosato
ITMI20110357A1 (it) Sistema microfluidico per scopi di analisi e di diagnosi, nonchè corrispondente procedimento per produrre un sistema microfluidico
WO2012056451A3 (fr) Marqueurs géniques du sang périphérique destinés au diagnostic précoce de la maladie de parkinson
WO2012158780A3 (fr) Signature du cancer du poumon
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
HK1214752A1 (zh) 由产甲烷菌引起或与之相关的疾病及病状的诊断、选择及治疗方法
WO2013124807A3 (fr) Oligonucléotides pour moduler l'expression de gènes et leurs utilisations
WO2012142409A3 (fr) Marqueurs de diagnostic et cibles thérapeutiques de la maladie de kawasaki
SG179129A1 (en) Method for identifying whether a patient will be responder or not to immunotherapy
WO2015007871A3 (fr) Micro-arn et maladie inflammatoire à médiation auto-immune
WO2014031881A3 (fr) Paires de gènes activité-dépendants à titre de cibles thérapeutiques et méthodes et dispositifs permettant de les identifier
IL234807A0 (en) Nucleic acid molecule capable of inhibiting expression of the periostin gene, method of inhibiting expression of the periostin gene and use of this nucleic acid molecule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13712154

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 112013001154

Country of ref document: DE

Ref document number: 1120130011549

Country of ref document: DE

REEP Request for entry into the european phase

Ref document number: 2013712154

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2013712154

Country of ref document: EP